STOCK TITAN

Insmed (INSM) CMO sells 12,302 shares after option exercises

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

INSMED Inc's Chief Medical Officer, Martina Flammer, reported an exercise-and-sell transaction in company stock. She exercised stock options to acquire a total of 12,302 shares of common stock at strike prices of $19.74 and $29.13 per share, then sold the same 12,302 shares in open-market trades at weighted average prices of $110.60 and $109.02 per share. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025, and she now holds 60,486 shares of common stock directly.

Positive

  • None.

Negative

  • None.
Insider Flammer Martina M.D.
Role Chief Medical Officer
Sold 12,302 shs ($1.35M)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 7,945 $0.00 --
Exercise Stock Option (right to buy) 4,357 $0.00 --
Exercise Common Stock 7,945 $29.13 $231K
Exercise Common Stock 4,357 $19.74 $86K
Sale Common Stock 4,854 $109.02 $529K
Sale Common Stock 7,448 $110.60 $824K
Holdings After Transaction: Stock Option (right to buy) — 23,835 shares (Direct, null); Common Stock — 68,431 shares (Direct, null)
Footnotes (1)
  1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 4,854 shares sold at prices ranging from $108.90 to $109.58 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 7,448 shares sold at prices ranging from $110.36 to $110.71 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Shares sold 12,302 shares Total common shares sold in open-market transactions on July 6, 2026
Sale price tranche 1 $110.60/share Weighted average for 7,448 shares sold
Sale price tranche 2 $109.02/share Weighted average for 4,854 shares sold
Options exercised (lot 1) 4,357 shares at $19.74/share Common stock acquired via option exercise
Options exercised (lot 2) 7,945 shares at $29.13/share Common stock acquired via option exercise
Post-transaction holdings 60,486 shares Common stock directly owned after all reported transactions
Trading plan adoption date February 27, 2025 Date Rule 10b5-1 trading plan was adopted
Option expiration dates 2033-01-05 & 2034-01-04 Expiration for the exercised stock option grants
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
vesting schedule financial
"The options become exercisable based on the following vesting schedule"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did INSMED (INSM) report for its Chief Medical Officer?

INSMED’s Chief Medical Officer, Martina Flammer, exercised stock options for 12,302 common shares and sold all 12,302 shares in open-market transactions. The activity reflects an exercise-and-sell pattern rather than a new open-market purchase of shares.

How many INSMED (INSM) shares did the CMO sell and at what prices?

Martina Flammer sold 12,302 INSMED common shares in total. She sold 7,448 shares at a weighted average price of $110.60 and 4,854 shares at a weighted average price of $109.02, based on price ranges disclosed in the filing.

What stock options did the INSMED (INSM) CMO exercise in this Form 4?

She exercised options covering 4,357 shares at a strike price of $19.74 and 7,945 shares at a strike price of $29.13. These exercises converted derivative stock options into common shares before the subsequent open-market sales.

How many INSMED (INSM) shares does the CMO own after these transactions?

Following the reported transactions, Martina Flammer directly owns 60,486 shares of INSMED common stock. This figure reflects her position after exercising stock options and selling 12,302 shares in open-market transactions on July 6, 2026.

Were the INSMED (INSM) insider sales made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were executed under a Rule 10b5-1 trading plan adopted on February 27, 2025. Such plans pre-schedule trades, indicating the timing was predetermined rather than based on new, discretionary decisions.

What does the vesting footnote on the INSMED (INSM) stock options mean?

The footnote explains that 25% of the options vest on the first anniversary of the grant date, with an additional 12.5% vesting every six months through the fourth anniversary. This schedule gradually makes more options exercisable over time as part of compensation.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Flammer Martina M.D.

(Last)(First)(Middle)
700 US HIGHWAY 202/206

(Street)
BRIDGEWATER NEW JERSEY 08807

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
INSMED Inc [ INSM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/06/2026M(1)7,945A$29.1368,431D
Common Stock07/06/2026M(1)4,357A$19.7472,788D
Common Stock07/06/2026S(1)4,854D$109.02(2)67,934D
Common Stock07/06/2026S(1)7,448D$110.6(3)60,486D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$29.1307/06/2026M(1)7,945 (4)01/04/2034Common Stock7,945$023,835D
Stock Option (right to buy)$19.7407/06/2026M(1)4,357 (4)01/05/2033Common Stock4,357$04,358D
Explanation of Responses:
1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
2. This is the weighted average sales price representing 4,854 shares sold at prices ranging from $108.90 to $109.58 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
3. This is the weighted average sales price representing 7,448 shares sold at prices ranging from $110.36 to $110.71 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
4. The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Remarks:
/s/ Martina Flammer, M.D., by Michael A. Smith as Attorney-in-fact07/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)